Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA SNORD41 (also known as U41, RNU41) is a member of the C/D box class of small nucleolar RNAs. SNORD41 is a non-coding RNA molecule that is predicted to guide site-specific 2'-O-methylation of ribosomal RNA, specifically the large 28S rRNA at residue U4276. It functions as part of small nucleolar ribonucleoprotein complexes (snoRNPs), binding with core proteins such as fibrillarin, NOP56, NOP58, and SNU13, to catalyze the chemical modification of rRNAs. These modifications are essential for rRNA stability, processing, and the accurate assembly and functioning of ribosomes in eukaryotic cells. SNORD41 is primarily localized in the nucleolus. While dysregulation of some snoRNAs has been implicated in cancer and other diseases, there is currently no evidence that SNORD41 itself acts as a therapeutic target or has established associations with specific diseases[4][2][3][1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA SNORD41 (SNORD41).